Oral iron deficiency therapy
Methods of normalizing iron levels, treating iron deficiency and disorders related thereto, such as anemia, as described. Pharmaceutical compositions effective for such treatments are also described.
1. A method of treating iron deficiency in a human patient comprising swallowing one or more immediate release solid oral dosage forms comprising a delivery agent and an iron compound, wherein the weight ratio of iron compound to the delivery agent is from about 2:1 to about 1:700, and wherein the delivery agent is selected from N-[8-(2-hydroxybenzoyl)amino]caprylic acid, N-(10-[2-hydroxybenzoyl]amino)decanoic acid, N-(8-[2-hydroxy-5-chlorobenzoyl]-amino)octanoic acid, 4-[(2-hydroxy-4-chloro-benzoyl)-amino]butanoic acid, 8-(2-hydroxyphenoxy)octyldiethanolamine, 8-(N-2-hydroxy-4-methoxybenzoyl)aminocaprylic acid, 3-toluoxybutanoic acid, and pharmaceutically salts thereof.
2. A method of treating anemia in a human patient comprising swallowing one or more solid oral dosage forms comprising a delivery agent and an iron compound, wherein the weight ratio of iron compound to the delivery agent is from about 2:1 to about 1:700, and wherein the delivery agent is selected from N-[8-(2-hydroxybenzoyl)amino]caprylic acid, N-(10-[2-hydroxybenzoyl]amino)decanoic acid, N-(8-[2-hydroxy-5-chlorobenzoyl]-amino) octanoic acid, 4-[(2-hydroxy-4-chloro-benzoyl)-amino]butanoic acid, 8-(2-hydroxyphenoxy) octyldiethanolamine, 8-(N-2-hydroxy-4-methoxybenzoyl)-aminocaprylic acid, 3-toluoxybutanoic acid, and pharmaceutically salts thereof.
3. The method of claim 1 , wherein the delivery agent is N-(8-[2-hydroxy-5-chlorobenzoyl]-amino)octanoic acid, or a pharmaceutically salt thereof.
4. The method of claim 1 , wherein the delivery agent is 3-toluoxybutanoic acid, or a pharmaceutically salt thereof.
5. The method of claim 1 , wherein the delivery agent is N-(10-[2-hydroxybenzoyl]amino)decanoic acid, or a pharmaceutically salt thereof.
6. The method of claim 1 , wherein the delivery agent is 4-[(2-hydroxy-4-chloro-benzoyl)-amino]butanoic acid, or a pharmaceutically salt thereof.
7. The method of claim 1 , wherein the delivery agent is 8-(2-hydroxyphenoxy)octyldiethanolamine, or a pharmaceutically salt thereof.
8. The method of claim 1 , wherein the delivery agent is 8-(N-2-hydroxy-4-methoxybenzoyl)-aminocaprylic acid, or a pharmaceutically salt thereof.
9. The method of claim 1 , wherein the human patient has chronic kidney disease.
10. The method of claim 1 , wherein the human patient is undergoing dialysis.
11. The method of claim 1 , wherein the human patient has Crohn's disease.
12. The method of claim 1 , wherein the human patient has cancer.
13. The method of claim 1 , wherein the human patient has gastritis or Celiac disease.
14. The method of claim 1 , wherein the dosage form is a tablet.
15. The method of claim 1 , wherein the delivery agent is a monosodium salt of N-[8-(2-hydroxybenzoyl)amino]caprylic acid.
16. The method of claim 1 , wherein the iron compound is ferrous sulfate, or a hydrate thereof.
17. The method of claim 1 , wherein the weight ratio of iron compound to the delivery agent is from about 1:2 to about 1:100.
18. The method of claim 1 , wherein the weight ratio of iron compound to the delivery agent is from about 1:3 to about 1:20.
19. The method of claim 1 , wherein the weight ratio of iron compound to the delivery agent is from about 1:4 to about 1:10.
20. The method of claim 2 , wherein the weight ratio of iron compound to the delivery agent is from about 1:2 to about 1:100.
21. The method of claim 2 , wherein the weight ratio of iron compound to the delivery agent is from about 1:3 to about 1:20.
22. The method of claim 2 , wherein the weight ratio of iron compound to the delivery agent is from about 1:4 to about 1:10.